Cardiff Oncology Inc. (NASDAQ: CRDF) presented preclinical data on its PLK1 inhibitor onvansertib combined with trastuzumab deruxtecan at the American ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE